Switch to:
More From Other Websites
Issue of unlisted options under ESOP New Oct 20 2016
Annual Report for the year ended 30 June 2016 New Oct 20 2016
Notice of Annual General Meeting New Oct 20 2016
Conversion of Convertible Notes Sep 13 2016
Novogen secures key US drug study approval Sep 12 2016
US FDA Approves Investigational New Drug (IND) Application for Cantrixil(TM) (TRX-E-002-1) in... Sep 11 2016
Resignation/appointment of Company Secretary Sep 11 2016
FDA approves IND application for Cantrixil Sep 11 2016
Novogen Announces FDA Approves IND Application for Cantrixil in Ovarian Cancer Sep 11 2016
Novogen appoints Scientific Advisory Board to guide development of oncology pipeline Sep 04 2016
Appendix 4E and Full Year Statutory Accounts Aug 30 2016
Novogen appoints Key Management Personnel to drive transition to a development-focused organisation Aug 28 2016
Novogen Submits IND Application to the US FDA for Cantrixil in Ovarian Cancer Aug 14 2016
Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in... Aug 11 2016
Novogen Patent Covering Anisina(TM) Has Proceeded to Grant Jun 13 2016
Novogen Patent Covering Anisina Has Proceeded to Grant Jun 13 2016
Edison Investment Research Report maintains valuation as Novogen resumes 100% ownership of Cantrixil May 09 2016
Novogen Provides Update On Development Of Cantrixil May 01 2016
Novogen Provides Update on Development of Cantrixil May 01 2016
Cantrixil (TRXE-002-1) Abstract (AACR Annual Meeting 2016) Apr 17 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)